| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | prima-1 | CTRPv2 | pan-cancer | AAC | 0.061 | 0.05 |
| mRNA | BRD-A94377914 | CTRPv2 | pan-cancer | AAC | 0.086 | 0.05 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.11 | 0.05 |
| mRNA | tosedostat | CTRPv2 | pan-cancer | AAC | 0.071 | 0.05 |
| mRNA | ELCPK | CTRPv2 | pan-cancer | AAC | 0.097 | 0.06 |
| mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.06 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | 0.06 | 0.06 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | 0.074 | 0.06 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.065 | 0.06 |
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | 0.073 | 0.06 |